椎体转移瘤调强放疗与三维适形放疗后骨密度与疼痛反应的随机试验次要结果
这项单中心随机探索性试验的预设次要分析纳入60例脊柱转移瘤姑息放疗患者,随机接受IMRT或3DCRT(30 Gy/10次)。两组3、6个月骨密度较基线均显著升高且组间无差异;IMRT组3个月VAS评分改善,但Chow标准疼痛反应两组相似;病理骨折率无差异。作者建议未来开展更大样本随机研究。
要点
- 两组3、6个月骨密度较基线均显著升高,IMRT与3DCRT组间无统计学差异。
- IMRT组3个月VAS评分改善(p=0.037),6个月无差异;Chow标准疼痛反应两组相似。
- 3个月病理骨折率IMRT组15.0% vs 3DCRT组10.5%,3、6个月均无差异。
核心结论
- 这是首个评估IMRT与3DCRT对骨密度影响的前瞻性研究。
- 两组3、6个月骨密度显著升高且相似,疼痛反应与病理骨折率亦无差异。
- 作者建议未来开展更大样本量的随机研究。
研究设计与样本
- 单中心随机探索性试验的预设次要分析,共纳入60例脊柱转移瘤姑息放疗患者。
- 患者随机接受IMRT或3DCRT,剂量方案为30 Gy分10次。
- 在基线、3个月和6个月评估受照与未受照椎体的定量骨密度,并记录病理骨折与椎体压缩骨折发生率。
- 疼痛反应采用视觉模拟量表(VAS)和Chow标准评估。
主要发现
- IMRT组骨密度较基线在3个月和6个月分别中位升高24.8%和33.8%(p < 0.01和p = 0.048)。
- 3DCRT组骨密度较基线在3个月和6个月分别中位升高18.5%和48.4%(两者p < 0.01)。
- IMRT与3DCRT组间骨密度在3个月(p = 0.723)和6个月(p = 0.341)均无统计学差异。
- 溶骨性和成骨性转移亚组分析两组间无差异;混合性转移中IMRT组(而非3DCRT组)骨密度较基线升高。
- 3个月病理骨折率IMRT组15.0% vs 3DCRT组10.5%,3个月(p = 0.676)和6个月(p = 1.000)均无差异。
关键数值与推荐
- 放疗剂量方案为30 Gy分10次,IMRT与3DCRT两组相同。
- 疼痛反应采用VAS和Chow标准评估。
- 骨密度在基线、3个月和6个月于受照和未受照椎体进行定量评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文标题注明为随机试验的次要结果。
- 作者在结论中建议未来开展更大样本量的随机研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This was a prespecified secondary analysis of a randomized trial that analyzed bone density and pain response following fractionated intensity-modulated radiotherapy (IMRT) versus three-dimensional conformal radiotherapy (3DCRT) for palliative management of spinal metastases. METHODS/MATERIALS: Sixty patients were enrolled in the single-institutional randomized exploratory trial, randomly assigned to receive IMRT or 3DCRT (30 Gy in 10 fractions). Along with pain response (measured by the Visual Analog Scale (VAS) and Chow criteria), quantitative bone density was evaluated at baseline, 3, and 6 months in both irradiated and unirradiated spinal bodies, along with rates of pathologic fractures and vertebral compression fractures. RESULTS: Relative to baseline, bone density increased at 3 and 6 months following IMRT by a median of 24.8% and 33.8%, respectively (p < 0.01 and p = 0.048). These figures in the 3DCRT cohort were 18.5% and 48.4%, respectively (p < 0.01 for both). There were no statistical differences in bone density between IMRT and 3DCRT at 3 (p = 0.723) or 6 months (p = 0.341). Subgroup analysis of osteolytic and osteoblastic metastases showed no differences between groups; however, mixed metastases showed an increase in bone density over baseline in the IMRT (but not 3DCRT) arm. The 3-month rate of the pathological fractures was 15.0% in the IMRT arm vs. 10.5% in the 3DCRT arm. There were no differences in pathological fractures at 3 (p = 0.676) and 6 (p = 1.000) months. The IMRT arm showed improved VAS scores at 3 (p = 0.037) but not 6 months (p = 0.430). Using Chow criteria, pain response was similar at both 3 (p = 0.395) and 6 (p = 0.732) months. CONCLUSIONS: This the first prospective investigation evaluating the impact of IMRT vs. 3DCRT on bone density. Along with pain response and pathologic fracture rates, significant rises in bone density after 3 and 6 months were similar in both cohorts. Future randomized investigations with larger sample sizes are recommended. TRIAL REGISTRATION: NCT, NCT02832830 . Registered 14 July 2016.
引用
- Sprave T, Verma V, Förster R, et al. Bone density and pain response following intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for vertebral metastases - secondary results of a randomized trial. Radiat Oncol. 2018. PMID: 30376859. doi:10.1186/s13014-018-1161-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。